Stocks Health care MAZE
NASDAQ · Health careMaze Therapeutics, Inc. (MAZE)
It posted a net loss of $151.5M. In fiscal 2025 capital spending exceeded operating cash flow by $112.7M. At September 30, 2026 it held $154.2M in cash against $39.1M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Maze Therapeutics, Inc.
- Net worth
- Maze Therapeutics, Inc. has a market value (market cap) of $1.9B at the latest share price, and shareholders' equity of $428.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $167.5M, with net income of $52.2M.
- Cash flow
- In fiscal 2025 operations used $111.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Maze Therapeutics, Inc.'s next report is expected around March 24, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Maze Therapeutics, Inc. does
Maze Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker MAZE.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$131.1M | -$3.05 | -$112.7M |
| 2025 | $167.5M | $52.2M | $1.25 | $74.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Maze Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 9, 2026
- October 16, 2026
- August 17, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026
- August 11, 2026
- July 29, 2026Passive stake (5% or more) SCHEDULE 13G
- June 10, 2026
- May 22, 2026
Insider trades
What the people running Maze Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $6.2M worth of shares in the last 90 days and bought none on the open market. Most of the selling (82%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 2, 2026 | Coloma Jason VChief Executive Officer, Director | Soldpre-planned (10b5-1), indirect | 2,257 | $68K |
| November 2, 2026 | Coloma Jason VChief Executive Officer, Director | Soldpre-planned (10b5-1), indirect | 336 | $10.4K |
| November 2, 2026 | Coloma Jason VChief Executive Officer, Director | Soldpre-planned (10b5-1), indirect | 26,563 | $799.4K |
| November 2, 2026 | Coloma Jason VChief Executive Officer, Director | Soldpre-planned (10b5-1), indirect | 5,345 | $166K |
| October 29, 2026 | Dandekar AtulCSBO | Exercised options | 6,643 | $69.2K |
| October 29, 2026 | Dandekar AtulCSBO | Exercised options | 857 | $8.9K |
| October 29, 2026 | Dandekar AtulCSBO | Soldpre-planned (10b5-1) | 7,500 | $240.5K |
| October 1, 2026 | Coloma Jason VChief Executive Officer, Director | Soldpre-planned (10b5-1), indirect | 2,593 | $70.1K |
Who owns MAZE
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| ARCH Venture Fund X, L.P.13G, passive with 8 related filers | 9.4% | May 15, 2025 |
| Third Rock Ventures IV, L.P.13G, passive with 5 related filers | 9.3% | February 13, 2026 |
| Deep Track Capital, LP13G, passive with 2 related filers | 9.02% | August 14, 2025 |
| Frazier Life Sciences Public Fund, L.P.13G, passive with 13 related filers | 9% | February 13, 2026 |
| Janus Henderson Group PLC13G, passive | 5.8% | May 15, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 162 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 5,032,915 | +465,641 |
| Trv GP IV, LLC | 4,473,958 | 0 |
| ARCH Venture Management, LLC | 4,120,053 | 0 |
| Deep Track Capital, LP | 3,732,569 | +255,007 |
| BlackRock, Inc. | 3,502,841 | +932,416 |
| Jupiter Topco LLC | 3,408,045 | new |
| Logos Global Management LP | 1,935,000 | +700,000 |
| Vanguard Capital Management LLC | 1,778,222 | +342,566 |
| a16z Capital Management, L.L.C. | 1,702,225 | 0 |
| Venrock Adviser, LLC | 1,602,034 | 0 |
| Alphabet Inc. | 1,388,583 | 0 |
| Braidwell LP | 1,140,040 | new |
| Farallon Capital Management, L.L.C. | 1,107,814 | +734,814 |
| Fmr LLC | 1,056,959 | +192,745 |
| General Catalyst Group Management, LLC | 1,035,910 | 0 |
| State Street Corp | 997,533 | +360,811 |
| Driehaus Capital Management LLC | 954,886 | +318,724 |
| Trv GP V, LLC | 950,800 | 0 |
| Jpmorgan Chase & Co | 964,011 | +905,565 |
| Marshall Wace, Llp | 914,572 | +603,933 |
Insiders
5 insiders reported holding 297,664 shares in total, about $10.3M at the last price.
| Holder | Shares |
|---|---|
| Coloma Jason VChief Executive Officer, Director | 214,263186,901 held indirectly |
| Dandekar AtulCSBO | 32,316 |
| Homcy Charles JDirector | 31,113 |
| Bachrodt AmySVP, Finance | 12,965 |
| Courtney PhillipsGC and Corp. Secretary | 7,007 |
Questions about MAZE
What does Maze Therapeutics, Inc. do?
Maze Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as MAZE. Its shares trade on NASDAQ under the ticker MAZE.
What is Maze Therapeutics, Inc.'s net worth?
Maze Therapeutics, Inc. has a market value (market cap) of $1.9B at the latest share price, and shareholders' equity of $428.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Maze Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $151.5M.
When did Maze Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Maze Therapeutics, Inc.'s next earnings report?
Maze Therapeutics, Inc.'s next report is expected around March 24, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare MAZE with
Follow MAZE
Get an email when Maze Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Maze Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.